Evaluation of the Therapeutic Effectiveness of Combined Action Antiallergic Drugs in Monotherapy of Allergic Conjunctivitis

According to statistical studies in recent decades, there has been an increase of allergic diseases in most countries of the world. Predisposing factors are the deterioration of the environmental situation, the total “chemicalization” of life and the forced use of drugs. Twenty years ago, the World Health Organization called the new century “the century of allergies” and the disease itself as an “epidemic”. As time has shown, these forecasts have come true: from 2001 to 2010, the number of allergic people in the world increased by 20 % and many of these patients suffer from ophthalmic manifestations of the pathology: the eyes are involved in the process in almost every second case. This is due to the fact that the eyes are directly exposed to the environment and a variety of external allergens. The most common disease of an eye-allergic nature is allergic conjunctivitis: approximately 15 % of the total population of economically developed countries suffer from it. Allergic blepharitis, eyelid dermatitis, keratitis, iritis, uveitis, retinitis and optic neuritis are much less common.
The following manifestations are typical for allergic conjunctivitis: burning, lacrimation, pruritus, hyperemia of the eyelids and conjunctiva, photophobia. In the case of a transition to a chronic form, pronounced tissue changes are observed. Therefore, timely diagnosis and effective treatment certainly have a positive effect on the quality of life of the patient and the course of the disease. The treatment of patients with allergic conjunctivitis, first of all, consists in the maximum possible restriction of contact with the allergen. During desensitizing therapy, local and general drugs are used. Numerous studies have proven the advantage of targeted and effective antiallergic local therapy compared with systemic exposure. Currently used local ophthalmic antiallergic drugs belonging to various groups. The tactics of their use is determined by the acuity, severity and etiology of the process. When choosing a drug, in some cases, you should focus on the presence of substances that provide a double mechanism of action: a pronounced antihistamine activity in combination with the stabilization properties of mast cells, which has a quick and long therapeutic effect. This study evaluated efficacy of Vizallergol (olopatadin 0.2 %) application in cases of allergic conjunctivitis in 239 patients was evaluated. The medication arrested the symptoms of allergic conjunctivitis in 89 % of patients, at that the mean period of treatment made 10.7 ± 0.3 days. In the treatment of allergic conjunctivitis, the therapeutic efficacy of Vizallergol 0.2 % was comparable to opatanol 0.1 % and was found to be more comfortable for most patients due to the convenience of a single use.

allergic conjunctivitis, allergen, degranulation, conjunctiva, edema, chemosis, compliance

1. Gelardi M., Leo M.E., Quaranta V.N., Iannuzzi L., Tripodi S., Quaranta N., Canonica G.W., Passalacqua G.J. Allergy Clin. Immunol. Pract., 2015;3(3):387–391. DOI: 10.1016/j.jaip.2015.01.006

2. Akdis M., Akdis C.A., Akdis M. Mechanisms of allergen-specific immunotherapy: multiple supressor factors at work in the immune tolerance to allergens. J. Allergy Clin Immunol. 2014;133(3):621–631. DOI: 10.1016/j.jaci.2013.12.1088

3. Lin S.Y.N., Erekosima J.M., Kim M., Ramanathan C., Suarez-Cuervo Y., Chelladurai D., Ward J.B., Segal L. Sublingual immunotherapy for the treatment of allergic rhinoconjuctivitis and asthma: a systematic review Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA. 2013;27;309(12):1278–1288. DOI: 10.1001/jama.2013.2049

4. Brzhesky V.V. Allergic conjunctivitis: a guide for an outpatient ophthalmologist. Russian Medical Journal. Medical Review = Rossijskij medicinskij zhurnal. Medicinskoe obozrenie. 2018;1(II):74–79 (In Russ.).

5. Egorov E.A., Muratova N.V. Allergic eye diseases (clinic and treatment): a reference guide. Moscow, 1998. 62 p. (In Russ.).

6. Neroev V.V., Vakhova E.S. Allergic conjunctivitis. Ophthalmology: National Guide. Moscow: GEOTAR-Media, 2018. P. 442–456 (In Russ.).

7. Bielory L., Chafoor S. Histamine receptors and the conjunctiva. Curr. Opin. Allergy Clin. Immunol. 2005;95(4):361–371. DOI: 10.1097/01.all.0000183113.63311.11

8. Galatowich G., Ajayi Y., Stern M.E., Calder V.L. Ocular anti — allergic compounds selectively inhibit human mast cell cytocines in vitro and conjunctival cell infiltration in vivo. Clin. Exp. Allergy. 2007;37(11):1648–1656. DOI: 10.1111/j.13652222.2007.02782.x

9. Bae J.M., Choi Y.Y., Park C.O., Chung K.Y., Lee K.H. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systemic review and meta-analysis of randomized controlled trials. J. Allergy Clin Immunol. 2013;132:110–117.

10. Maychuk Yu.F. Opatanol (olopatadine 0.1 %) — eye drops of a double antiallergic mechanism of action. Russian Medical Journal. Clinical Ophthalmology = Rossijskij medicinskij zhurnal. Klinicheskaya oftal’mologiya. 2007;(2):63 (In Russ.).

11. Anisimov S.I. Combined drugs in the modern therapy of infectious and inflammatory lesions of the eyes of bacterial etiology. Russian Medical Journal. Clinical Ophthalmology = Rossijskij medicinskij zhurnal. Klinicheskaya oftal’mologiya. 2010;(30):874 (In Russ.).

12. Shvets S.M. Allergic conjunctivitis and modern approaches to its therapy. Russian Allergy Journal = Rossijskij allergologicheskij zhurnal. 2012;(4):56–63 (In Russ.).

13. Richter A., Anton S.E., Koch P. The impact of reducing dose frequency on health outcomes. Clin. Ther. 2003;25(8)2307–2335. DOI: 10.1016/s0149-2918(03)80222-9

14. Abelson M.B., Spangler D.L., Epstain A.B. Efficacy of once-daily Olopatadine 0,2 % ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenges. Curr. Eye Res. 2007;32(12):1017–1022. DOI: 10.1080/02713680701736558

15. Vogelson C.T., Abelson M.B., Pasquine T. Preclinical and clinical antiallergic effect of Olopatadine 0,2 solution 24 hours after topical ocular administration. Allergy Asthma Proc. 2004;2(1):69–75. DOI: 10.2147 / opth.s3294

16. Brocman H.L., Momsem M.M., Knudtson J.R., Miller S.L., Graff G., Yanni J.M. Interactions of olopatadine and selected antihistamines with model and natural membranes. Ocul. Immunol. Inflamm. 2003;11(4):247–268. DOI: 10.1076/ ocii.11.4.247.18261

17. Lichtenshtein S., Paskin T., Edwards M., Wells D., Gross R., Robertson S. Safety and tolerability of olopatadin 0.2 % in children and adolescents. Journal of ocular pharmacology and therapeutics. 2007;23(4):137–141. DOI: 10.1089 / jop2007.0013

18. Egorov E.A., Astakhov Yu.S., Stavitskaya T.V. General principles of drug treatment of eye diseases. Clinical Ophthalmology = Klinicheskaya oftal’mologiya. 2004;1:2 (In Russ.).